Trial Profile
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary) ; Cyclophosphamide; Doxorubicin; Topotecan; Vincristine
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATLANTIS
- Sponsors PharmaMar
- 01 Feb 2024 Results of post-hoc analysis of two studies NCT02454972 and NCT02566993, published in the Lung Cancer.
- 24 Oct 2023 Results assessing the occurrence of chemotherapy-induced myelosuppression events with standard of care chemotherapies for relapsed SCLC and supportive care interventions from NCT02454972, NCT02514447 and NCT02566993, presented at the 48th European Society for Medical Oncology Congress.
- 08 Sep 2023 According to a PharmaMar media release, result data from this study will be presented at The International Association for the Study of Lung Cancer (IASLC) held in Singapore from September 9th to 12th.